Drugmaker Pfizer reported a $306 million loss in its fourth quarter after it shifted its consumer health business into a joint venture last year. The company narrowly missed Wall Street's profit expectations.
The biggest U.S. drugmaker, on Tuesday reported net loss of 6 cents per share. In the year-ago quarter, Pfizer lost $394 million, or 7 cents per share.
Adjusted earnings of $3.11 billion just missed the $3.24 billion expected by analysts surveyed by FactSet.
Revenue totaled $12.69 billion in the October-December quarter. That topped the $12.61 billion that analysts were expecting, but was 9% lower than a year earlier. Sales in emerging markets like China and India jumped 14%.
Pfizer’s innovative prescription drug business posted revenue of $10.53 billion in the quarter, led by Prevnar 13, Eliquis, rheumatoid arthritis pill Xeljanz and breast cancer pill Ibrance.
Its Upjohn business, which sells off-patent drugs such as Lipitor and Viagra, had revenue of $2.16 billion in the latest quarter.
In premarket trading, Pfizer shares fell 42 cents, or 1.1%, to $39.74.
The company has been steadily working through a major slim down to focus on developing innovative new drugs.
Last July, Pfizer moved its huge stable of nonprescription medicines into a new joint venture with partner GlaxoSmithKline. Pfizer owns 32% of the JV, which brought Pfizer a profit of $129 million in the quarter. Meanwhile, Pfizer plans to combine its Upjohn business with generic drugmaker Mylan by mid-summer to create a new drugmaker called Viatris.
Pfizer noted it has three recently approved biosimilar drugs, near-copies of pricey biologic drugs “manufactured” in living cells, that have just launched or will by mid-February. Those are versions of three widely used cancer drugs, Herceptin, Avastin and Rituxan. The biosimilars are being sold for nearly 25% less than the list price of the now off-patent brand-name version as Pfizer aims to be atop seller of these injected medicines.
Pfizer also noted that during 2019, it spent $8 billion on shareholder dividends and $8.9 billion on share repurchases.
Pfizer Inc., based in New York, forecast adjusted net income of $2.82 to $2.92 per share, on revenue of $48.5 billion to $50.5 billion, for all of 2020.
___
Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report